He is an internationally recognized orthopedic surgeon. He is an inventor and holder of more than 50 US patents in medicine and surgery. He was one of the pioneers in arthroscopic surgery and as such most recognized as the inventor of the motorized instrumentation still used world wide today in all such procedures.
Lanny L. Johnson, M.D. is the founder of AntiOxidant USA Research and Development
In 2018 he was invited to submit the following manuscript to the Bone and Joint Journal that reflected upon his career; a short autobiographical article.
Johnson LL. What’s Important: Making a Difference May Include Being Different. J Bone Joint Surg. 2018 Mar 7; 100 (5): 443. DOI 10.2106/JBJS.18.00011.
After concluding his clinical practice he has continued his interest in medical research and development. In 2005, upon learning of the effect of the dyes that give color to cherries to stimulate the rodent pancreatic cells to produce insulin, he reasoned there may be other applications. Independent studies at Scripps Institute in La Jolla, California confirmed his hypothesis that these dyes would cause the human joint lining to turn on the growth factor gene for Insulin Like Growth Factor-1. IGF-1 has long been known to heal articular cartilage. This resulted in US patents for intra articular injection treatment of synovial joint arthritis; i.e. knee, hip, shoulder, etc.
8, 263,069 Compositions including anthocyanin or anthocyanidins for the prevention or treatment of articular cartilage-associated conditions. September 11, 2012.
9,486,468: Compositions including anthocyanin or anthocyanidin for the prevention or treatment of articular cartilage-associated conditions. November 8, 2016
While waiting for these patents to be issued, he learned from the medical literature that various plant extracts having these dyes, anthocyanins and anthocyanidins had anti bacterial properties. He commissioned independent in vitro laboratory studies that showed the parent dyes were weak antibiotics. However the primary metabolites; protocatechuic acid (PCA) and 2,4,6 tri-hydroxybenzaldehyde (246THBA) were very powerful broad spectrum antibiotics. The subsequent metabolites, vanillic and hippuric acid had littleanti biotic properties.
As a result of these studies he was granted US patent on these primary metabolites for their anti bioitic and wound healing properties.
9,498,413: B2 Antimicrobials and methods of use thereof for wound healing. November 22, 2016.
All Natural Ingredients
Antioxidant & Anti-inflammatory
These studies on wound healing also demonstrated that PCA would produce more collagen in the skin following tape stripping of the rodent skin. This study method replicated the clinical procedures of exfoliation or dermabrasion. US patent claims have been granted for this application as USA patent No. 9,925,152 that was issued on March 27, 2018.
Subsequently, he funded a two-year, four phase human proof of principle study in attempt to sanitize the skin in human volunteers at Loma Linda Medical School. This was performed on medical student volunteers. He was seeking a means of disinfecting the human skin prior to surgery since the bacteria of the skin are one source of surgical infections. Attention was given especially to Propionibacterium acnes which in recent years as emerged as the bacteria uniquely causing shoulder and spine surgery infections. One result from these studies was the discovery of an antioxidant formulation that would control the various potential pathogens on normal skin while preserving the comensal normal bacteria.
He also commissioned studies at WuXiapptec of Marietta GA from which he learned that PCA in certain concentrations would destroy the biofilm covered colonies of serious pathogens; Methicillin Resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. This lead to US patents granted concerning the coating of medical and surgical implants to prevent wound infections following total knee and total hip surgery.
He has an application underway with the Environmental Protection Agency concerning a spray for hard surfaces that will be helpful in hospitals and clinics to sanitize these environments of pathological microbes.
He envisions PCA as being the basis for a new industry, addressing multiple health, humanitarian and societal problems.
He launched OAUSA R&D in 2018 to meet those needs.
He is holder of the following US patents related to the many applications of PCA:
See the individual published patent by copying the number and going to: http://patft.uspto.gov/
As or September 2018 the following US patents have been granted. The United States Patent number is followed by the title of the patent. These are available for review on the US patent office web site. The easiest way to see the claims and the supporting scientific evidence is to go to: http://patft.uspto.gov/netahtml/PTO/srchnum.htm This site allows you to type in the patent number, a very quick way to view all the credible evidence. To be clear, all of the following patents about PCA are applications not related to the oral intake. The oral intake patents are pending.